Skip to main content
. 2017 Nov 16;12(11):e0187839. doi: 10.1371/journal.pone.0187839

Fig 1. Metabolic activity and AST levels of human hepatocytes after treatment with levosimendan.

Fig 1

(A) The metabolic activity of human hepatocytes increased after 24 hour treatment with levosimendan after I/R injury in a dose-dependent manner. (B) After a 48 hour treatment with levosimendan after I/R injury, the metabolic activity is increased but there is no dependency detectable. (C) Normoxic and ischemic/reperfused human hepatocytes were compared regarding metabolic activity after a 24 hour treatment with levosimendan. After I/R the protective effect of levosimendan is amplified compared to normoxic groups. (D) AST levels of ischemic/reperfused hepatocytes are significantly reduced after 48 hour treatment with levosimendan compared to 24h treatment. Human hepatocytes are treated with 10ng/ml (D1), 100 ng/ml (D2) and 1000ng/ml (D3) levosimendan. Saponin served as positive control. Untreated but ischemia/reperfused hepatocytes served as control. (each experiment n = 3), # p<0.05 vs ctr., § p<0.05 vs pos. ctr., * p<0,05.